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New Insights on
Stent Thrombosis
In Praise of Large Nationwide Registries for
Rare Cardiovascular Events*
Fernando Alfonso, MD, PHD, Jorge Sandoval, MD
Madrid, Spain
Stents represent the default strategy in interventional car-
diology (1). In the last decade, drug-eluting stents (DES)
have been widely embraced because of their unprecedented
ability to drastically inhibit neointimal proliferation. Ac-
cordingly, the clinical need for repeat revascularization has
been significantly reduced despite the widespread use of
coronary interventions in ever increasingly complex clinical
and anatomic scenarios. However, the risk of stent throm-
bosis (ST) remains an issue of serious concern (2). DES
have been unable to reduce the incidence of this complica-
tion but have changed its temporal pattern of presentation,
widening the vulnerable period. Actually, this problem has
prevented an even wider penetration of DES (1,2).
See page 131
ST remains a very rare phenomenon, but it may be
associated with devastating clinical consequences (2). Early
series suggested that ST was associated with very high
mortality (3). Subsequent studies—from less selected pa-
tient populations—suggested that the consequences of ST
were not so dismal, although clinical outcomes were still
poorer than those seen in de novo patients with acute
myocardial infarction (4,5). The explanation for this partic-
ularly adverse prognosis remains obscure, but the uniquely
large thrombus burden seen in patients with ST might play
a role (2). Likewise, the underlying mechanisms leading to
ST remain poorly elucidated but appear multifaceted. Me-
chanical factors, delayed endothelialization, and hypersen-
sitivity reactions have all been considered as “local factors”
able to generate a “vulnerable stent.” Furthermore, from a
“systemic” perspective, any potent stimulus triggering plate-
let activation might shift the delicate coagulation balance
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isclose.toward a prothrombotic milieu precipitating the acute event.
However, despite intense research efforts, the incidence,
predictive factors, underlying pathological substrate, clinical
implications, and management of ST still remain incom-
pletely elucidated. All previous studies on ST suffer from a
common main limitation: relatively small sample sizes.
Therefore, larger studies, with enough power to address the
unmet need of information still required on this dreadful
complication, are eagerly awaited.
In this issue of JACC: Cardiovascular Interventions, Arm-
strong et al. (6) present the results of an impressively large
cohort of patients with ST (7,315 episodes of ST) included in
the CathPCI Registry. This study provides unique insights
that complement our current knowledge on ST.
Present Study
In the current study, 7,079 patients with ST (1,391 early
[19.6%], 1,370 late [19.4%], and 4,318 very late [61%]), of
401,662 patients (1.8%) with acute coronary syndromes
prospectively included in the CathPCI Registry, were ana-
lyzed (6). Two-thirds of patients received DES and expe-
rienced very late ST. Overall in-hospital mortality was only
4.5% and was similar for bare-metal stents (BMS) and DES
ST. Patients with early ST showed a higher prevalence of
black race, diabetes, and prior heart failure. They also
presented more frequently a Thrombolysis In Myocardial
Infarction (TIMI) flow grade 0 and left anterior descending
coronary artery lesions. Interestingly, in-hospital mortality
was 2-fold higher (7.9%) in patients with early compared
with late or very late ST. Notably, the poorer clinical
outcome of patients with early ST persisted despite adjust-
ment for potential confounders using a previously validated
mortality model. Of additional interest, more than one-half
of the interventions performed to treat episodes of ST
eventually involved a new stent implantation. However, the
use of thrombus aspiration devices and glycoprotein IIb/IIIa
platelet inhibitors (GPI) (one-third and two-thirds of proce-
dures, respectively) was relatively limited. Early ST was more
frequently managed with GPI but also had a higher incidence
of major bleedings. To fully appreciate the importance of the
novel information unraveled by this study, its results should
be examined from the perspective gained during the discus-
sion of some relevant methodological issues.
In addition to its uniquely large sample size, this study
has many major strengths. Assessing data quality and
potential selection biases are always of paramount impor-
tance for the interpretation of large registries. The CathPCI
Registry is an initiative of the American College of Cardi-
ology and the Society for Cardiovascular Angiography and
Interventions, with quality standards validated by the Na-
tional Cardiovascular Data Registry. Briefly, data elements
were prospectively collected during hospitalization in con-
secutive patients using explicit definitions (6). In addition,
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142several quality checks—including external audits—were im-
plemented to ensure data reliability. All patients had angio-
graphically confirmed (i.e., definitive) ST. Moreover, to
better adhere to the Academic Research Consortium defi-
nition and further refine the study cohort, avoiding potential
misclassifications, strict additional requirements were man-
dated. These included careful crosschecking of the dataset
to guarantee consistency of pertinent clinical and angio-
graphic variables. For instance, additional description of
angiographic thrombus was required for patients with TIMI
flow grade 3 (6). On the other hand, nearly 1,000 U.S.
centers participated in this study, dissipating any potential
concern on external validity. Finally, the selected cross-
sectional design offered a very recent (years 2009 to 2010)
and tight (16-month time window) snapshot on current
clinical practices implemented in patients with ST (6).
Some potential study limitations should be also consid-
ered. First, angiographic studies were not centrally reviewed
in a core laboratory (6). However, due to the strict screening
criteria, the risk of misclassification of angiographically
confirmed ST appears negligible. Second, adverse events
were not adjudicated by an independent committee. Nev-
ertheless, consecutive patients were enrolled, and authors
selected total death as the primary endpoint, which, again, is
highly reassuring. However, only patients with ST under-
going coronary interventions were included, and this may
lead to survival bias. Other adverse events, in particular
recurrent episodes of ST, are relatively frequent in these
patients, yet neither data on these episodes nor the require-
ment of target vessel revascularization were collected. Like-
wise, many earlier reports suggested that these patients have
an adverse prognosis after discharge. However, long-term
clinical information was not obtained. Furthermore,
compliance to antiplatelet medication was not recorded.
Finally, the cross-sectional study design allows assessing
the burden posed by this problem on routine real-world
catheterization laboratory “activity” but provides no inci-
dence estimates (6).
Treatment of Stent Thrombosis
Despite the widespread concern generated in the cardiovas-
cular scientific community by the problem of ST, it is
surprising to realize the scarce information currently avail-
able on the value of specific therapies for the management of
these patients (2–5). The rarity of this complication, which
always conveys a medical emergency, has likely impeded the
design of adequate studies aimed to gain the required
evidence on the relative efficacy of different interventional
modalities. Most investigators, including our own group,
suggest a holistic approach to address this challenging
scenario (2–9). First, an aggressive management of the
intracoronary thrombus (thrombus aspiration, intracoronary
GPI) appears warranted. Second, any effort should be made cto remove all residual, potentially predisposing mechanical
factors (stent fracture, underexpansion, malapposition, edge
dissections, inflow–outflow disease) for ST (2,7–9). The use
of intracoronary diagnostic techniques (intravascular ultra-
sound or optical coherence tomography) appears of major
value to guide and optimize results of these interventions
(7–9). Third, a truly “effective” preventive antiplatelet reg-
imen should be initiated immediately and then maintained
for a long time, ideally, indefinitely. The value of systematic
use of point-of-care functional tests to assess on-treatment
platelet reactivity, or genetic screening tests to disclose
adverse polymorphisms, currently remains unproven. How-
ever, they certainly constitute attractive options in the
individual patient to ensure that the prescribed antiplate-
let therapy is being effective. A more pragmatic approach
would be the use of the newer, more potent and predict-
able antiplatelet agents in all patients with ST. In any
case, the thrombogenic milieu should be urgently and
aggressively reverted, because survivors of ST may not
survive recurrences (2–5).
From a mechanical standpoint, careful thrombus aspira-
tion appears essential (7–11). Recent studies suggest that in
these patients, thrombus aspiration is associated, not only
with better epicardial and microvascular reperfusion (10),
ut also with favorable clinical outcomes (11). Following
hrombus removal, one would anticipate that an aggressive
ilation of the underlying stent would be adequate to
ptimize final results in most patients. In this regard, the
igh number of patients eventually requiring a new stent
mplantation in this series is surprising (6). Interestingly, the
ate of new stent placement was lowest and the use of GPI
ighest among patients with early ST (6). The reasons for
hese distinct treatment patterns remain unknown. How-
ver, prior studies (5) and a recent registry from California
12) also suggested that most patients treated for ST
eceived a second stent. Although the value of recurrent
tent implantation (stent-in-stent technique) is well estab-
ished in patients with in-stent restenosis (ISR), its role in
he setting of ST remains highly controversial. Unfortu-
ately, this registry was unable to ascertain why some of
hese patients eventually required a repeat stenting. There-
ore, we can only speculate as to why this strategy was
elected in most patients. Re-stenting is able to readily
rovide satisfactory angiographic results, even in patients
ith persisting suboptimal results after balloon inflation
ecause of resistant in-stent thrombus. Although covering
he thrombus with another stent might not be perceived as
n elegant strategy, this may constitute the last resort option
n some cases. Another possibility is that the new stent was
ust used to tackle edge dissections or significant obstructive
isease adjacent to the original stent. Actually, residual edge
issections and inflow–outflow disease, together with de
ovo plaque rupture adjacent to the stent, are well-known
auses of ST that can be easily “fixed” with overlapping
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143stents (7–9). Finally, edge dissections may be also generated
during the procedure by the use of relatively oversized balloons
in the attempt to optimize final angiographic results.
New Evidence Bridging the Gap Between
Restenosis and Thrombosis
In some patients, it might be difficult to differentiate severe
ISR from true ST due to overlapping clinical and angio-
graphic features. Moreover, the possibility of underlying
ISR associated with superimposed thrombosis in some
patients with non-early ST, as discussed by Armstrong et al.
(6) in their report, is intriguing indeed. Interestingly, complete
essel occlusion was less frequent in patients with non-early
T. This might be the result of a smaller thrombus burden,
hich in turn may explain the lower use of GPI and the higher
se of repeat stenting in this patient subset. Again, we could
nly speculate on whether this might have contributed to
Figure 1. Optical Coherence Tomography Images of a Patient With Very Late
In-stent optical coherence tomography images (A to D) from a patient prese
eluting stent in the left anterior descending coronary artery. Angiography only
thrombi. (A) Severe homogeneous neointimal hyperplasia, the stent struts, and
pletely shadowing the stent struts (consistent with lipid-laden or inﬁltrated ne
75 m) (yellow arrows) with underlying cavities (), together with large, pro
All the images were obtained within the stent. This patient, with an initial clin
myocardial infarction (creatine phosphokinase peak 750 IU).he lower mortality of patients with non-early ST. The
emonstration of neoatherosclerosis in some patients with
SR represents a major paradigm shift in the field that may
elp to bridge the gap between the 2 worlds. Recent studies
ith coronary angioscopy, intravascular ultrasound, and
ptical coherence tomography have demonstrated the pres-
nce of thin-cap fibroatheroma, lipid-laden neointima, ne-
rotic core, plaque rupture, neovascularization, and more
mportantly, superimposed red or white thrombi in some
atients presenting with unstable symptoms and late/very
ate ISR/ST (13–16) (Fig. 1). Pathological observations (17)
onfirmed these phenomena, further suggesting that late
n-stent neoatherosclerosis, not only occurs more frequently,
ut also occurs earlier after DES than after BMS. Currently,
his specific substrate may be identified with intracoronary
maging techniques and represents yet another etiology of
vulnerable stents” (13–17). Interestingly, many of these
nt Restenosis Presenting as ST
with prolonged chest pain 3 years after the implantation of an everolimus-
nstrated a severe, diffuse, in-stent restenosis without images suggestive of
e microvessels (6 o’clock) are clearly visualized. (B) Bright neointima com-
a). (C and D) Images of disrupted intima or ruptured thin cap (thickness
g red thrombi (T) causing major distal shadowing of the stent. *Wire artifact.
agnosis of in-stent restenosis, eventually evolved as a relatively large anteriorIn-Ste
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144patients do not suffer from large myocardial infarctions and
appear to have less severe thrombotic burden (13–17).
Although it is tempting to speculate that the distinct
pathological substrate of complicated late in-stent neoath-
erosclerosis might have a relatively favorable prognosis and
require the use of specific coronary interventions, these
exciting hypotheses should be confirmed in prospective
studies.
Final Remarks
This uniquely large, high-quality registry provides novel
important information on clinical characteristics, current
therapeutic strategies, and prognosis of patients suffering
from ST. Although, in unselected consecutive patients
undergoing reinterventions, in-hospital mortality appears to
be lower than previously reported, this rare but feared
complication still remains associated with significant mor-
bidity and mortality. Management of ST remains highly
challenging, and additional evidence is urgently warranted
to be able to select from our current therapeutic armamen-
tarium the best possible pharmacomechanical approach,
ideally tailored to the characteristics of individual patients.
However, here, more than ever, prevention should remain
the cornerstone of any therapeutic effort.
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